中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2009年
8期
828-830
,共3页
肝硬化%阿德福韦酯%拉米夫定
肝硬化%阿德福韋酯%拉米伕定
간경화%아덕복위지%랍미부정
Liver cirrhosis%Adefovi%Lamivudine
目的 比较肝炎肝硬化失代偿患者应用核苷类似物抗病毒治疗前后临床和病理方面的变化,探讨其抗病毒治疗的必要性、疗效和安全性.方法 选择肝炎肝硬化失代偿患者80例,根据肝穿病理结果将其分为3组:拉米夫定组、阿德福韦酯组和对照组,常规保肝治疗相同,拉米夫定组加用拉米夫定片0.1g/d;阿德福韦酯组加用阿德福韦酯酯胶囊10 mg/d,对照组不用任何抗病毒及调节免疫的药物,疗程36周,定期监测肝肾功能、凝血酶原时间(PTA)、HBV DNA定量指标,计算Child-Pugh分值,对部分肝穿组织病理变化进行比较.结果 拉米夫定组及阿德福韦酯组Child-Pugh评分分别降低为3.9分和2.1分;HBV DNA定量分别降低为(4.1±0.9)copies/ml和(2.8±1.0)copies/ml;肝脏炎症积分均减少2以上;肝纤维化积分减少1以上,与对照组比较差异均有统计学意义(P均<0.05).结论 肝炎肝硬化失代偿患者应用核苷类药物抗病毒治疗后临床与病理方面均有明显改善,抗病毒治疗对于肝炎肝硬化失代偿期非常必要且安全.
目的 比較肝炎肝硬化失代償患者應用覈苷類似物抗病毒治療前後臨床和病理方麵的變化,探討其抗病毒治療的必要性、療效和安全性.方法 選擇肝炎肝硬化失代償患者80例,根據肝穿病理結果將其分為3組:拉米伕定組、阿德福韋酯組和對照組,常規保肝治療相同,拉米伕定組加用拉米伕定片0.1g/d;阿德福韋酯組加用阿德福韋酯酯膠囊10 mg/d,對照組不用任何抗病毒及調節免疫的藥物,療程36週,定期鑑測肝腎功能、凝血酶原時間(PTA)、HBV DNA定量指標,計算Child-Pugh分值,對部分肝穿組織病理變化進行比較.結果 拉米伕定組及阿德福韋酯組Child-Pugh評分分彆降低為3.9分和2.1分;HBV DNA定量分彆降低為(4.1±0.9)copies/ml和(2.8±1.0)copies/ml;肝髒炎癥積分均減少2以上;肝纖維化積分減少1以上,與對照組比較差異均有統計學意義(P均<0.05).結論 肝炎肝硬化失代償患者應用覈苷類藥物抗病毒治療後臨床與病理方麵均有明顯改善,抗病毒治療對于肝炎肝硬化失代償期非常必要且安全.
목적 비교간염간경화실대상환자응용핵감유사물항병독치료전후림상화병리방면적변화,탐토기항병독치료적필요성、료효화안전성.방법 선택간염간경화실대상환자80례,근거간천병리결과장기분위3조:랍미부정조、아덕복위지조화대조조,상규보간치료상동,랍미부정조가용랍미부정편0.1g/d;아덕복위지조가용아덕복위지지효낭10 mg/d,대조조불용임하항병독급조절면역적약물,료정36주,정기감측간신공능、응혈매원시간(PTA)、HBV DNA정량지표,계산Child-Pugh분치,대부분간천조직병리변화진행비교.결과 랍미부정조급아덕복위지조Child-Pugh평분분별강저위3.9분화2.1분;HBV DNA정량분별강저위(4.1±0.9)copies/ml화(2.8±1.0)copies/ml;간장염증적분균감소2이상;간섬유화적분감소1이상,여대조조비교차이균유통계학의의(P균<0.05).결론 간염간경화실대상환자응용핵감류약물항병독치료후림상여병리방면균유명현개선,항병독치료대우간염간경화실대상기비상필요차안전.
Objective To evaluate the clinicophatholgic benefits and safty of antivirus therapy in patients with liver cirrhosis resulting from hepatitis B.Methods 80 patients with HBV-ralated liver cirrhosis were divided into three groups by the histopathology of liver:group of lamivudine treated with lamivudine 100 mg once daily;Adefovir group treated with Adefovir 10 mg once daily;control group treated with liver protective treatment only.Liver and renal function,PTA and HBV DNA were regularly measured.The Child push-Turotte sore and histopathology wag compared before and after treatment.All courses of treatment were 36 weeks.Results The scores of Child Pugh-Turotte sore in groups of lamivudine and Adefovir were lowered sinificantly (3.9 and 2.1 respectively),the load of HBV-DNA was decreased also[(4.1±0.9) copies/ml and(2.8±1.0) copies/ml],liver inflammmation decreased by more than 2 scores and liver fiber was improved by more than one score,with obviously significant difference(P<0.05) as compared with control group.Conclusion Patients with HBV-related cirrhosis treated with lamivudine and adefovir for antivims are improved and antivirus is important and safe to those during cirrhosis decompensation.
